Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201404-02 Lead development: Development of drug candidates for rheumatoid arthritis using immunomodulatory cytokine(Immunology, Protein) [08.05.2014]

PRINT

Development and Market Objectives

Rheumatoid arthritis (RA) is characterized by pathogenic mechanisms that include synovial inflammation as well as the progressive destruction of cartilage and bone.
 
Particularly, CD4+ T-helper cells that express interferon (IFN)-γ and interleukin (IL)-17 (TH1 and TH17 cells) and macrophages, which are infiltrated in synovium, are considered to be the main drivers in the pathogenesis of RA.
 
Recently, various approaches, such as specific monoclonal antibodies against inflammatory cytokines and chemical inhibitors, have been widely undertaken for RA treatment.
 
However, they have not yet been sufficient unmet medical need, because the targets usually are end product and/or involved in only one pathway function at the downstream.
 
We previously reported that immunomodulatory cytokline, CIB13034H transiently affected MHC class II expression on B cells via increasing cAMP.
 
Here we demonstrated that CIB13034H, which may function at upstream, ameliorated RA symptom in a mouse model in vivo via suppressing differentiation of TH1 and TH17 cells as well as activation of macrophage.
 
Moreover, CIB13034H generally inhibited LPS-triggered inflammation.
 
Our observation suggests that tIK cytokine can systemically function as a counterbalance against inflammatory cells, which are related with RA induction, and thus, it could become new therapeutic agent for the treatment of RA.

Unmet Medical Need & Target Patients

1) Target Patient
Rheumatoid arthritis is a chronic auto-inflammatory disease characterized by polyarthritis. The inflammation at joint membrana sinovial cause destruction of cartilage and bone that leads to destruction and modification of joint. The anemia, scleratitis, pulmonary diseases, vasculitis and osteoporosis may occur as a result.
 
Rheumatoid arthritis has been shown that 0.2 male per 1,000 and 0.4 female per 1,000 annually and has relatively even prevalence of 0.4%~1.0% around the world.
 
 
2) Unmet Medical Needs
Current rheumatoid arthritis drugs such as non-steroidal anti-inflammatory drugs (NSAID), steroids, conventional disease modifying anti-rheumatic drugs (DMARD) and biological disease modifying anti-rheumatic drugs (bDMARDs) are unsatisfying to maintaining low disease activity and may cause side effect after long-term medication.
 
Most of current rheumatoid arthritis are antibody therapeutics that shows no medical effects approximately at 30% of rheumatoid arthritis patient. Also, very high priced and may occur complications with pneumonia, tuberculosis, herpes zoster and suppuration.
 
Therefore, the new rheumatoid arthritis therapeutic agent with less or none side-effects is urgently needed.

Status

A new peptide candidates derived from immune response control cytokine has been secured.

Intellectual Property

Korean patent application No.10-2014-0038809 (2014. 01. April)
PCT application No. PCT/KR2014/003282 (2014. 24. April)

Competitive Advantages

As existing drugs of rheumatoid arthritis have several controversial points such as 1) efficacy avoidance 2) high price 3) side effects, the effect of treatment is limited. 

CIB13034H drug has a new meaning as a biological drug aims new target over antibody drugs for inflammatory cytokine. 

Indication

Immunology  (Rheumatoid arthritis)

Research Period

Jul., 2014 ~ Aug., 2015

Company

Cellinbio co., ltd

Developmental Stage

Lead generation

Additional Information

Contact Information

Contact
Address Company Name: Cellinbio co., ltd
WebSite Homepage: http://www.cellinbio.co.kr Contact Person: Jung, Hana
E-mail: hjung@cellinbio.co.kr Contact: + 82-31-695-7959

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code